Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Clinical trial NCT05766514 · WITHDRAWN
Trial details
- NCT number
- NCT05766514
- Sponsor
- University of Florida
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2029-12-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.